BioTime, Inc. BTX-Product Pipeline Analysis, 2016 Update

BioTime, Inc. BTX-Product Pipeline Analysis, 2016 Update


  • Products Id :- GDME225PD
  • |
  • Pages: 44
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

BioTime, Inc. (BioTime) is a biotechnology company with focus on regenerative medicine and plasma volume expanders. The company's Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. The company is also developing Renevia to facilitate cell transplantation; AST-VAC1 autologous (patient-specific) cancer vaccine; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); AST-OPC1 for spinal cord injury rehabilitation; HyStem hydrogel products; and mobile health software products. The company's products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. The company's products are developed on its pluripotent stem technology based on induced pluripotent stem (iPS) cells and human embryonic stem (hES) cells. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

The report analyzes all pipeline products in development for the company BioTime, Inc.

The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

The report provides detailed description of products in development, technical specification and functions

The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons To Buy:

Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

To formulate effective Research & Development strategies

Develop market-entry and market expansion strategies

Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

BioTime, Inc. Company Snapshot 6

BioTime, Inc. Company Overview 6

BioTime, Inc. Pipeline Products and Clinical Trials Overview 7

BioTime, Inc.-Pipeline Analysis Overview 9

Business Description 9

Key Facts 10

BioTime, Inc.-Major Products and Services 11

BioTime, Inc. Pipeline Products by Development Stage 12

BioTime, Inc. Clinical Trials by Trial Status 14

BioTime, Inc. Pipeline Products Overview 16

BioTime Films 16

BioTime Films Product Overview 16

BioTime Sponges 17

BioTime Sponges Product Overview 17

HyStem Renevia 18

HyStem Renevia Product Overview 18

HyStem Renevia Clinical Trial 19

HyStem-Spine 20

HyStem-Spine Product Overview 20

HyStem-Tendon 21

HyStem-Tendon Product Overview 21

PanC-Dx-Bladder Cancer 22

PanC-Dx-Bladder Cancer Product Overview 22

PanC-Dx-Bladder Cancer Clinical Trial 23

PanC-Dx-Breast Cancer 24

PanC-Dx-Breast Cancer Product Overview 24

PanC-Dx-Breast Cancer Clinical Trial 25

PanC-Dx-Colon Cancer 26

PanC-Dx-Colon Cancer Product Overview 26

PanC-Dx-Lung Cancer 27

PanC-Dx-Lung Cancer Product Overview 27

PanC-Dx-Prostate Cancer 28

PanC-Dx-Prostate Cancer Product Overview 28

ReGlyde 29

ReGlyde Product Overview 29

BioTime, Inc.-Key Competitors 30

BioTime, Inc.-Key Employees 31

BioTime, Inc.-Key Employee Biographies 32

BioTime, Inc.-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 35

BioTime, Inc., Recent Developments 35

Dec 30, 2015: BioTime Announces "When-Issued" Trading of Subsidiary OncoCyte in Connection With Planned Distribution 35

Nov 24, 2015: LifeMap Solutions Appoints Robert W. Peabody Chief Financial Officer 35

Nov 18, 2015: BioTime Announces the Appointment of Life Sciences Industry Veteran Russell Skibsted as Chief Financial Officer 35

Nov 09, 2015: BioTime Reports Third Quarter 2015 Results and Recent Corporate Accomplishments 36

Nov 04, 2015: LifeMap Sciences, a Subsidiary of BioTime, and Lab7 Systems Announce Partnership and Launch of Integrated NGS Analysis Solution 39

Oct 19, 2015: Adi Mohanty Joins Michael D. West, PhD, as Co-CEO of BioTime 40

Sep 29, 2015: LifeMap Solutions Announce Initial Results for Asthma Health App and New Features to Enhance Clinical Impact 41

Sep 29, 2015: Mount Sinai and LifeMap Solutions Announce Initial Results for Asthma Health App and New Features to Enhance Clinical Impact 41

Sep 14, 2015: BioTime Subsidiary OncoCyte Appoints Cavan Redmond to its Board of Directors 42

Sep 02, 2015: ESI BIO-A Division of BioTime Launches New Research Technology Platform, VascuNet Pericyte Co-Culture Assay 42

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44

List of Figures

BioTime, Inc. Pipeline Products by Equipment Type 8

BioTime, Inc. Pipeline Products by Development Stage 12

BioTime, Inc. Clinical Trials by Trial Status 14

List of Tables

BioTime, Inc. Pipeline Products and Clinical Trials Overview 7

BioTime, Inc. Pipeline Products by Equipment Type 7

BioTime, Inc. Pipeline Products by Indication 8

BioTime, Inc. Clinical Trials by Trial Status 8

BioTime, Inc., Key Facts 10

BioTime, Inc., Major Products and Services 11

BioTime, Inc. Number of Pipeline Products by Development Stage 12

BioTime, Inc. Pipeline Products Summary by Development Stage 13

BioTime, Inc. Clinical Trials by Trial Status 14

BioTime, Inc. Clinical Trials Summary 15

BioTime Films-Product Status 16

BioTime Films-Product Description 16

BioTime Sponges-Product Status 17

BioTime Sponges-Product Description 17

HyStem Renevia-Product Status 18

HyStem Renevia-Product Description 18

HyStem Renevia-Pivotal Clinical Trial of Renevia for HIV-associated Lipoatrophy 19

HyStem-Spine-Product Status 20

HyStem-Spine-Product Description 20

HyStem-Tendon-Product Status 21

HyStem-Tendon-Product Description 21

PanC-Dx-Bladder Cancer-Product Status 22

PanC-Dx-Bladder Cancer-Product Description 22

PanC-Dx-Bladder Cancer-An Observational Clinical Study to Validate the Performance of OncoCyte's Proprietary Diagnostic Technology 23

PanC-Dx-Breast Cancer-Product Status 24

PanC-Dx-Breast Cancer-Product Description 24

PanC-Dx-Breast Cancer-Clinical Study of PanC-Dx for Breast Cancer and Other Types of Human Cancers 25

PanC-Dx-Colon Cancer-Product Status 26

PanC-Dx-Colon Cancer-Product Description 26

PanC-Dx-Lung Cancer-Product Status 27

PanC-Dx-Lung Cancer-Product Description 27

PanC-Dx-Prostate Cancer-Product Status 28

PanC-Dx-Prostate Cancer-Product Description 28

ReGlyde-Product Status 29

ReGlyde-Product Description 29

BioTime, Inc., Key Employees 31

BioTime, Inc., Key Employee Biographies 32

BioTime, Inc., Subsidiaries 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

BioTime, Inc., Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies

select a license

Single User License
USD 750 INR 48263
Site License
USD 1500 INR 96525
Corporate User License
USD 2250 INR 144788

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com